That one is now totally discredited. To me, comes across as a fool (or t..l), rather than an agenda driven 'influencer'
Whatever ... the 'fundamentals' viewpoint is ludicrous; the 'mid next year' claim is fictitious; and the claim of negative 'bottom line' is obvious if we are to run P3 trial(s) - they ARE costly, and will effect the bottom line, but given 2591 results to date POTENTIALLY lucrative (i.e. fundmentally very sound).
At this stage, risk vs. reward it has got to be a buy for those who accept a bit of risk.
Ann: Update - Notification of buy-back - NEU, page-131
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
-0.140(1.07%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $4.627M | 354.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7585 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 3344 | 2 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |